JAKARTA, Indonesia, March 17, 2026 /PRNewswire/ — The IWIP Charity Foundation is part of the Yongqing Group, which is owned by Tsingshan Industrial Holdings has donated 8MWh of GFM ESS solutions to two remote Indonesian islands to help build stable and reliable power systems.

PT Dogo Teknologi Energi (DoGo) is providing the GFM ESS solution. DoGo’s leading technology and extensive experience in grid-forming ESS enabled them to deliver a comprehensive solution, including an 8MWh storage system, a power conversion system (PCS), and communication and management systems. DoGo also spearheaded the design, grid simulation and consulting services, ensuring that the system can autonomously establish a stable power supply network and effectively address the challenges of island off-grid operations.

This donation initiative also serves as a positive demonstration. In August 2025, the Indonesian government set itself the ambitious goal of accelerating the nation’s transition to clean energy. The initiative involves constructing 100 GW of solar energy and 320 GWh of battery storage capacity in 80,000 villages and centralised solar power plants, thereby accelerating the transformation of the energy infrastructure. Grid-connected energy storage solutions offer a feasible and scalable development path for remote islands, mining areas, and ‘power islands’, improving overall electricity accessibility and providing practical solutions to help the country achieve its new energy development goals and offering practical references for the country’s new energy development goals.

The IWIP Charity Foundation stated that this donation is a significant step towards the company proactively fulfilling its social responsibilities and committing to global energy sustainability. By deploying GFM ESS solutions on remote islands, the company intends to support improvements to local livelihoods through concrete action, bridge the energy access gap between regions and ensure that more people benefit from clean energy development.

A new residency program invites guests to experience a dialogue between creative vision and immersive hospitality

SHANGHAI, March 17, 2026 /PRNewswire/ — In celebration of this year’s Hong Kong Art Month, Luxury Group by Marriott International unveils “Art of Arrival”, a new artist residency program that invites emerging Chinese artist Chen Zuo to present a journey across place and perspective. Through an immersive residency, a commissioned piece, and an international exhibition circuit, “Art of Arrival” transforms arrival into a creative journey – inviting guests and audiences to experience the intersection of place, imagination, and design.

“Luxury today is defined by moments of arrival and cultural relevance that leave lasting personal meaning,” said Bart Buiring, Managing Director, Luxury, Greater China, Marriott International. “With ‘Art of Arrival,’ we reaffirm our commitment to offering more than refined stays. We create immersive cultural encounters, where each arrival is more than reaching a destination. It becomes a moment where art and life intersect, inspiring a narrative unique to that place.”

From Suzhou to the World: An Artistic Journey Across Spaces
The inaugural chapter of “Art of Arrival” unfolded in Suzhou. During his residency at The Ritz-Carlton, Suzhou, Chen Zuo drew inspiration from the city’s classical gardens, waterways, urban architectures, and the sculptural presence of Taihu scholar’s stones. These interwoven strands of nature and built environment, which define the destination, grounded his new commissions created during the residency.

For Chen Zuo, the residency represented a fundamental recalibration of creative rhythm. “It granted me the rare gift of unhurried focus – time to observe, reflect, and evolve my practice within a complex cultural framework,” said Chen Zuo. “When the residency is integrated into the creative process itself, the work develops with heightened clarity and purpose.”

The resulting artwork will premiere in late March during Hong Kong Art Month, with a private presentation at The St. Regis Hong Kong. This event will bring together collectors, gallerists, and cultural key opinion leaders to witness the next chapter of Chen Zuo’s artistic journey. The artwork will then travel to Art Basel in Switzerland, where it will be exhibited in collaboration with Galerie Urs Meile, taking its Chinese narrative to a broader international platform. The program culminates in a Greater China tour across select Luxury Group properties, featuring private salons, collector gatherings, and artist talks that foster the dialogue between contemporary art and hospitality, enriching the narrative’s dimensions across multiple destinations.

Cinematic Storytelling: Capturing the Movement of Inspiration
To fully document the creative journey of this residency, Luxury Group has partnered with Tatler China to produce a short documentary tracing Chen Zuo’s path, beginning in his Beijing studio to Suzhou’s gardens and canals, and ultimately to Hong Kong’s international unveiling. Structured around moments of observation and immersion, the film captures the quiet momentum of creation, embodying ‘Art of Arrival’s’ core tenet: authentic creativity born from careful attention rather than spectacle. The film will premiere in late March across official brand platforms, including Marriott Bonvoy’s WeChat channel.

Luxury Travel Reimagined Through Artistic Encounters
At the heart of Wan Chai, The St. Regis Hong Kong collaborates with Hong Kong’s premium sparkling tea brand Mindful Sparks and local artist Elsa Ngai to create a unique, limited-edition sparkling tea experience for guests. Inspired the signature fragrance “Caroline’s Four Hundred,” the tea’s tasting notes are reflected in a bespoke bottle adorned with Elsa Ngai’s artwork – capturing both the vibrancy of Hong Kong’s cityscape and the hotel’s timeless elegance. This collaboration offers guests a memorable blend of art, flavor, and local creativity.

During the Hong Kong Art Month, Luxury Group properties advance this cultural conversation through curated artistic programming. JW Marriott Hotel Hong Kong collaborates with internationally recognized sculptor Richard X. Zawitz to reimagine the 34^th floor into the “Infinity Guestroom Floor,” shaped by his signature aesthetic of “Curvism”. Beginning March 18, the hotel presents a two-week solo exhibition that seamlessly integrates sculpture into the guest experience. The Ritz-Carlton, Hong Kong features “Dialogue of Stillness and Resilience,” a site-specific art installation by Angus Ting, founder of esteemed local bamboo craft brand “Yiwooo”. Displayed in the 103^rd floor lobby from March 17 to April 8, the work responds to the rhythm of daily life and ambient light, offering guests a moment of contemplation above the city’s hustle.

Through “Art of Arrival”, Luxury Group by Marriott International introduces a new approach to cultural engagement, moving beyond static exhibitions toward ongoing artistic collaboration. Art becomes not simply something to observe during travel, but something to experience, engage with, and discover along the journey. Each arrival becomes an opportunity for inspiration. As the program evolves, Luxury Group by Marriott International remains committed to exploring the intersections of art, culture, and lifestyle, crafting experiences that deepen the connection between destinations, creativity, and the modern traveler.

About Luxury Group by Marriott International  
With an unrivaled portfolio of eight dynamic luxury brands, Marriott International is creating authentic, rare, and enriching experiences sought by today’s global luxurian. Spanning all corners of the world, Marriott International’s Luxury Group offers a boundless network of more than 555 landmark hotels and resorts in 74 countries and territories through The Ritz-Carlton, Ritz-Carlton Reserve, Bvlgari Hotels & Resorts, St. Regis Hotels & Resorts, EDITION, The Luxury Collection, JW Marriott, and W Hotels. From the world’s most iconic destinations to the ultimate undiscovered gems, the international hospitality leader’s collection of luxury brands is focused on elevating travel with highly contextualized, nuanced brand experiences that signal the future of luxury by allowing guests to indulge their passions while sparking personal growth. For more information, please visit Luxury.Marriott.com.  

About Marriott Bonvoy®
Marriott Bonvoy’s extraordinary portfolio offers renowned hospitality in the most memorable destinations in the world, with more than 30 brands that are tailored to every type of journey. From The Ritz-Carlton and St. Regis to W Hotels and more, Marriott Bonvoy has more luxury offerings than any other travel program. Members can earn points for stays at hotels and resorts, including all-inclusive resorts and premium home rentals, and through everyday purchases with co-branded credit cards. Members can redeem their points for experiences including future stays, Marriott Bonvoy Moments™, or through partners for luxurious products from Marriott Bonvoy Boutiques®. To enroll for free or for more information about Marriott Bonvoy, visit marriottbonvoy.com. 

About Galerie Urs Meile
Founded in 1992 in Lucerne, Galerie Urs Meile represents artists from both China and Europe across different generations and media – including painting, sculpture, installation, photography, and video. Active in China since 1995, the gallery has played an important role in fostering dialogue between Eastern and Western contemporary art. Today, it operates spaces in Beijing, Zurich and Ardez, staging 14 to 16 exhibitions annually.

Galerie Urs Meile is dedicated to nurturing contemporary art in both China and Europe, fostering a productive dialogue between the two. It is committed to long-term relationships with artists and collectors, emphasizing sustained engagement and collaboration. By fostering connections that transcend generational and cultural boundaries, the gallery supports the growth of vibrant art communities, bringing diverse perspectives into the international spotlight. Serving as a counterbalance to art production driven solely by ideology or market forces, Galerie Urs Meile contributes actively to a cultural landscape enriched by diverse narratives and artistic expressions, contributing to a cultural prosperity.

With a new generation of collectors emerging in China and Europe, Galerie Urs Meile continues to play a vital role in bridging the gap between leading figures and young enthusiasts in contemporary art.

About Chen Zuo
Born in 1990 in Xiangxi, Hunan, Chen Zuo lives and works in Beijing. A graduate of the China Central Academy of Fine Arts and its affiliated fine arts school, where he completed both his undergraduate and master’s degrees in oil painting.

As a leading young artist in China’s contemporary art, Chen Zuo presented his first solo exhibition, Building Houses in the Forest at Galerie Urs Meile, Beijing, in 2023, systematically showcasing his artistic trajectory. His works have featured in major group exhibitions including the National Art Museum of China’s Unity and Diversity: New Forms in Contemporary Painting.

Chen Zuo’s paintings not only embody precise techniques and strict painting disciplines, but they are also full of emotions, containing richness and contingency, and are closely related to the daily experiences and memories of real life. As he notes, “I do not construct landscapes out of abstraction alone; I still require a sense of lived reality.”

Media Contact 
Patrick Faden
Director, Luxury Brand PR & Communications, Greater China 
Marriott International
Patrick.E.Faden@marriott.com   

PERTH, Australia, March 17, 2026 /PRNewswire/ — BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry, Manufacturing, and Controls) program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care settings.

Sterile injectable manufacturing using a closed isolator system, BioCina Perth

A reformulated RLS-2201 is being produced at BioCina’s sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys’ planned first-in-human clinical activities.

“We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in de-risking this program. Their collaborative approach to regulatory engagement gives us strong confidence as we move toward clinical trials. Together, we believe RLS-2201 has the potential to address a critical unmet need in the treatment of delirium in acute hospital settings,” said Dr. Samantha South, CEO, Patrys.

The initiation of CMC activities represents a significant de-risking step for the RLS-2201 program. By validating the manufacturing process for clinical readiness at this stage, Patrys and BioCina are establishing a technically sound and regulatorily defensible pathway toward clinical trial entry, targeted for the second half of 2026. This engagement further strengthens BioCina’s partnership with Patrys, reflecting BioCina’s commitment to supporting clients at every stage of their product development journey.

“We are thrilled to support Patrys’ journey for RLS-2201. BioCina’s 50 years of experience in the development and manufacturing of sterile injectables is more than just a capability. We ensure partners like Patrys can progress to clinic with confidence, and keep the focus where it belongs – improving patient outcomes,” said Dr. Tommy Broudy, CEO, BioCina.

About BioCina
BioCina is a global end-to-end Contract Development and Manufacturing Organisation (CDMO) with over 50 years of sterile Drug Product manufacturing experience, serving clients across the U.S., Europe, and Asia Pacific. With facilities recognised by the US FDA, EMA, TGA, and other key regulatory authorities, BioCina delivers Drug Substance and Drug Product solutions from early development through to commercial scale.

BioCina’s capabilities span sterile injectable manufacturing of small and large molecule products in multiple formats, as well as microbial biologics, pDNA, mRNA and LNP-based modalities. Partnering with BioCina in Australia provides clients with access to one of the world’s most attractive R&D tax incentive programs, offering a meaningful cost advantage throughout development and manufacture.

For more information, visit www.biocina.com

About Patrys
Based in Perth, Australia, Patrys, (ASX: PAB), is a clinical-stage biotechnology company advancing a dual-platform strategy combining innovative antibody therapeutics with a near-term CNS pharmaceutical program. Patrys’ deoxymab platform comprises novel cell-penetrating antibodies targeting intracellular disease mechanisms with a focus on immune-mediated inflammatory and other high-unmet-need indications.

Patrys’ CNS program, RLS-2201, is a proprietary injectable reformulation of quetiapine for the treatment of delirium in intensive, aged and palliative care setting, advancing via the FDA 505(b)(2) regulatory pathway. Together, these platforms position Patrys as a catalyst-rich, balanced development company, combining a de-risked reformulation asset with longer-term biologics innovation.

For more information, visit www.patrys.com

Media Contact
media@biocina.com

Photo – https://laotiantimes.com/wp-content/uploads/2026/03/patrys_release_image_250225_8335.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2026/03/biocina_new_logo.jpg

TOKYO, March 17, 2026 /PRNewswire/ — TIER IV, Inc. (headquartered in Shinagawa, Tokyo, Japan; Founder and CEO: Shinpei Kato; hereinafter TIER IV) and Isuzu Motors Limited (headquartered in Yokohama, Kanagawa, Japan; President and COO: Shinsuke Minami; hereinafter Isuzu) have announced the deployment of Level 4 autonomous buses, leveraging NVIDIA DRIVE Hyperion*1 computing platform, in Isuzu ERGA electric and diesel models. These next-generation autonomous transit vehicles will feature NVIDIA DRIVE AGX Thor system-on-chip*2 on the NVIDIA DRIVE Hyperion platform for essential safety and performance redundancy.

Timed to coincide with NVIDIA GTC 2026, the premier global AI conference held March 16-19 in San Jose, California, this announcement marks a major step toward TIER IV’s and Isuzu’s ambition to safely and scalably deploy autonomous transit. This effort combines TIER IV’s Level 4 software stack based on Autoware*3, open-source software for autonomous driving, Isuzu’s advanced bus platforms, and NVIDIA’s AI compute, to create Level 4 autonomous buses optimized for high-capacity public transit.

“This collaboration marks a definitive milestone for autonomous transit,” said Shinpei Kato, founder and CEO of TIER IV. “By fusing Isuzu’s legendary engineering with NVIDIA’s Thor AI compute, we have built an unmatched foundation for Level 4 transit driven by Autoware. Unveiling this Level 4 autonomous bus deployment at NVIDIA GTC 2026 proves that when you combine world-class hardware with the power of the Autoware ecosystem, safe and scalable public transit is no longer a goal – it is a reality.”

“Our partnership with TIER IV and NVIDIA represents a significant leap in commercial vehicle intelligence,” said Hiroshi Sato, Senior Executive Officer and Vice President, Engineering Division of Isuzu. “Deploying Level 4 autonomous driving on both our ERGA EV and diesel models ensures that we provide versatile, sustainable, and highly efficient solutions for any fleet. We are bringing Isuzu’s world-renowned reliability to the autonomous age, ensuring safe and high-performance transit at scale.”

“The transition to highly automated commercial transport demands fail-operational, high-performance computing without compromise,” said NVIDIA Vice President of Automotive Rishi Dhall. “TIER IV and Isuzu are frontrunners in the public transit vertical, utilizing NVIDIA DRIVE AGX Thor on the DRIVE Hyperion platform in the Isuzu ERGA to power TIER IV’s Autoware-based Level 4 software stack. Their scalable solution addresses critical real-world needs, such as Japan’s national driver shortage, while delivering the operational rigor necessary for essential public services.”

*1 A complete, production-ready autonomous driving development platform and reference architecture that combines a standardized sensor suite, high-performance AI computing, and a robust software stack to accelerate the development and deployment of autonomous vehicles.
*2 An automotive-grade system-on-chip that delivers up to 2,000 TFLOPS of performance, with ASIL-D compliance and redundancy for superior safety.
*3 Autoware is a registered trademark of the Autoware Foundation.

CONTACT: pr@tier4.jp

SHANGHAI, March 17, 2026 /PRNewswire/ — Monday, March 16^th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to accelerate the discovery of novel therapeutics with AI-driven designs with NVIDIA technology.

The collaboration highlights Viva Biotech’s “Lab-in-the-Loop” workflow, combining de novo computational design with high throughput protein production and biophysical evaluation to design ActRIIA binders. This integrated approach demonstrates how in silico predictions with real-world experimental validations can expedite drug discovery, showcasing the effectiveness of NVIDIA BioNeMo and Viva Biotech’s AI-driven integrated drug discovery platform in optimizing drug candidates.

As part of this effort, Viva Biotech leverages its AI technique for sequence selection and provide valuable feedback to improve the original Proteina-Complexa model. This iteration led to more efficient and targeted mini-binder designs. Guided by AI-driven insights, we successfully explored previously uncharted chemical space and significantly enhanced design specificity, achieving these advances at a fraction of the cost and time compared with conventional drug candidate nomination processes. For further details, please refer to the project paper: https://research.nvidia.com/labs/genair/proteina-complexa/.

As a leading contract research organization (CRO) that specializes in AI-driven drug discovery (AIDD) and structure-based drug discovery (SBDD), Viva Biotech combines computational modeling, generative AI, and extensive wet lab capabilities to accelerate the discovery of small molecules, antibodies, peptides, fusion proteins, PROTACs, molecular glues, and RNA-targeting compounds. Looking ahead, Viva Biotech will further strengthen its AI algorithm development and leverage its AI platform in drug discovery and development. The company will continue to enhance its process to deliver high-quality, impactful solutions for its partners as a leading force in the AI-driven drug discovery era.